- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

Phase III outcomes for type 2 diabetes treatment

DREAMS-2 Phase III outcomes for mazdutide have been published which could have transformative results for type 2 diabetes (T2D).

Mazdutide is reportedly the only glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist to reach Phase III stage of development for T2D globally.

DREAMS-2 Phase III study compared the efficacy and safety of mazdutide and dulaglutide in Chinese subjects with T2D, who have inadequate glycemic control with metformin monotherapy or a combination therapy of metformin with other oral drugs.

The primary endpoint was successfully met, showing the robust glucose-lowering efficacy of mazdutide. The key secondary endpoints showed mazdutide’s superior benefits in both lowering glucose and weight loss.

Amongst the seven GLP-1R/GCGR dual agonists being developed globally from Phase I to Phase III stages of clinical development, PB-718 (Phase I) and mazdutide, are from China.
Mazdutide is in Phase I clinical trials in the US and Phase II in Europe for T2D. Additionally, it is in the pre-registration stage in China for obesity treatment and is undergoing Phase II trials globally for the same indication.

Innovent Biologics Inc indicated that this news gives superiority over dulaglutide in glycaemic control for T2D patients in China. The company says that Mazdutide could reshape the landscape of diabetes therapeutics in China and also underscores the growing demand for innovative solutions amidst the escalating prevalence of T2D in the region.

- Advertisement -
Joanna Harvey
Joanna Harvey
Marketing and Communication Executive | Uniphar Commercial


- Advertisement -



Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription